ClinicalTrials.gg

Program

SI-B036

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Head and Neck Neoplasms · Breast Neoplasms · Digestive System Neoplasms · Urologic Neoplasms, led by Sichuan Biokin Pharmaceutical.

Furthest: phase 1, since May 19, 20267 company-led studies, 7 open or runningNext primary completion: Oct 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sichuan Biokin Pharmaceutical77 open or runningphase 1since May 19, 2026May 19, 2026Oct 2028phase 1 · NCT07857616

Also a collaborator on its studies: baili-bio-chengdu-pharmaceutical-co-ltd.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 19, 2026First study: phase 1 study in Solid TumorFirst studyNCT07606612 · 31 planned · China
  2. Jun 25, 2026Phase 1 study in Digestive System NeoplasmsNCT07678970 · 10 planned · China
  3. Jul 30, 2026Phase 1 study in Urologic NeoplasmsNCT07744243 · 30 planned · China
  4. Aug 4, 20263 phase 1 studiesNCT07753226, NCT07763639, NCT07778862
  5. Sep 22, 2026Phase 1 study in Carcinoma, Non-Small-Cell LungNCT07857616 · 424 planned · United States

Ahead

  1. Oct 2028Primary completion: phase 1 study in Carcinoma, Non-Small-Cell LungNCT07857616
  2. Dec 2028Primary completion: phase 1 study in Gynecological TumorsNCT07778862
  3. Dec 2028Primary completion: phase 1 study in Head and Neck NeoplasmsNCT07763639
  4. Dec 2028Primary completion: phase 1 study in Breast NeoplasmsNCT07753226

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07857616Carcinoma, Non-Small-Cell Lung · United States1RecruitingOct 2028424
NCT07778862Gynecological Tumors · China1Not yet recruitingDec 202830
NCT07763639Head and Neck Neoplasms · China1RecruitingDec 202830
NCT07753226Breast Neoplasms · China1RecruitingDec 202839
NCT07744243Urologic Neoplasms · China1Not yet recruitingDec 202830
NCT07678970Digestive System Neoplasms · China1RecruitingDec 202810
NCT07606612Solid Tumor · China1RecruitingDec 202831

How it is read

Names in the registry

  • “SI-B036”, 7 entries

Codes read as this program: SIB036.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.